Compare PRTA & CLMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTA | CLMB |
|---|---|---|
| Founded | 2012 | 1982 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.7M | 527.7M |
| IPO Year | 2013 | 1996 |
| Metric | PRTA | CLMB |
|---|---|---|
| Price | $9.27 | $27.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | $19.00 | ★ $80.00 |
| AVG Volume (30 Days) | ★ 312.7K | 116.9K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | N/A | ★ 14.29 |
| EPS | 0.26 | ★ 0.48 |
| Revenue | $814,000.00 | ★ $652,517,000.00 |
| Revenue This Year | $1,111.38 | $7.82 |
| Revenue Next Year | N/A | $5.83 |
| P/E Ratio | ★ $36.69 | $58.00 |
| Revenue Growth | N/A | ★ 40.14 |
| 52 Week Low | $7.73 | $15.25 |
| 52 Week High | $11.80 | $145.00 |
| Indicator | PRTA | CLMB |
|---|---|---|
| Relative Strength Index (RSI) | 49.71 | 46.65 |
| Support Level | $9.05 | $26.50 |
| Resistance Level | $9.36 | $29.10 |
| Average True Range (ATR) | 0.35 | 1.12 |
| MACD | 0.01 | -0.17 |
| Stochastic Oscillator | 44.40 | 21.87 |
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, United Kingdom, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.